Discovery of natural inhibitors that selectively target the substrate site of GSK-3β has materialized as a rational and realistic approach in AD drug discovery because ATP-site–directed GSK-3β inhibitors bind to many off-target kinases. This evidence concerns the gene GSK3B and Alzheimer disease.